A m⁶A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.

已完结 10 由哈哈哈发布于 2026/2/2 20:10:08

DOI:10.1007/s13402-022-00697-2
作者：Mengyuan Lei,?Chenghan Luo,?Jiayang Zhang,?Wenjun Cao,?Jian Ge,?Min Zhao
文献类型：期刊论文
补充材料：只需要正文

Springer

Abstract：Background: As the most abundant modification in mRNA, the N6-methyladenosine (m6A) RNA modification is involved in the occurrence and development of various tumors. However, the underlying

应助信息

8小时前

9wm9ldj

5ba9883a003111f1950634735aa3bc31.pdf 已采纳

8小时前

Book学术机器人

2026/2/2 20:10:08 未找到该文献，机器人已退出，请等待人工下载

2026/2/2 20:10:08 Book学术AI机器人收到请求，开始寻找文献

2026/2/2 20:10:08 已向机器人发送请求

8小时前

哈哈哈发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SagePrevalence and Site of Concomitant Osteochondral Injuries in Patients With Acute Lateral Patellar Dislocation: A Systematic Review and Meta-analysis.

A m6A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.

A m⁶A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.